Follow The Filings

FULC Fulcrum Therapeutics

Fulcrum Therapeutics earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.11 — —
Rev — — —

Insider trades

Open-market buys and sales by FULC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FULC insider trades
  • $1.5M bought by 1 insider
  • $58.4M sold by 1 insider outside a trading plan
  • $600K sold by 3 insiders under 10b5-1 plans
  1. Kevin Tang 10% owner, +1 joint filer
    Buy
    $595K 167,616 shares at $3.55 +2.4% to stake
    Traded Jul 16–17 Filed Jul 20
  2. Kevin Tang 10% owner, +1 joint filer
    Buy
    $891K 249,946 shares at $3.57 +3.8% to stake
    Traded Jul 13–15 Filed Jul 15
  3. Alan Ezekowitz Director
    Planned sale
    $66K 18,000 shares at $3.65 62% of stake
    Traded Jun 26 Filed Jun 30
  4. Robert J Gould Director
    Planned sale
    $163K 15,000 shares at $10.87 3.1% of stake
    Traded Jan 2 Filed Feb 4
  5. Robert J Gould Director
    Planned sale
    $161K 15,000 shares at $10.72 3.2% of stake
    Traded Feb 2 Filed Feb 4
  6. Curtis Gale Oltmans Chief Legal Officer
    Planned sale
    $45K 3,452 shares at $12.92 25% of stake
    Traded Dec 15, 2025 Filed Dec 17, 2025
  7. Ra Capital Management, L.P. 10% owner, +3 joint filers
    Sale
    $58.4M 4,175,139 shares at $13.98 41% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
  8. Robert J Gould Director
    Planned sale
    $165K 15,000 shares at $11.03 3% of stake
    Traded Nov 19, 2025 Filed Nov 21, 2025

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 1.01,3.02,5.01,5.02,7.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 5.02
SCHEDULE 13G —
10-Q
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —
8-K 5.07
8-K 5.02
SCHEDULE 13G —
8-K 2.05,8.01
8-K 8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
DEF 14A
DEFA14A
8-K 1.02,2.02,5.02,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.